International Trading Office Pharmaceutical Import Profile — Egypt (DGFT 2022–2026)

Name: International Trading Office Pharmaceutical Import Records from India — 2 Products, $526.2K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

International Trading Office — Pharmaceutical Importer Profile (2026) | 2 Products, $526.2K Trade | TransData Nexus

International Trading Office

Pharmaceutical Importer · Egypt · Immunosuppressants Focus · $526.2K Total Trade · DGFT Verified

International Trading Office is a pharmaceutical importer based in Egypt with a total trade value of $526.2K across 2 products in 1 therapeutic categories. Based on 13 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. International Trading Office sources from 2 verified Indian suppliers, with Rpg Life Sciences Limited accounting for 92.9% of imports.

International Trading Office — Import Portfolio & Supplier Network

International Trading Office import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to International Trading Office?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Rpg Life Sciences Limited	$963.7K	49	92.9%
Serum Institute Of India Private Limited	$73.9K	13	7.1%

International Trading Office sources from across .

What Formulations Does International Trading Office Import?

Formulation	Value	Ships
Mofetyl 500 MG tabs (3 x 10s)	$100.0K	2
Tablets/capsules arpimune 50MG	$100.0K	2
Azathioprine 50 MG tablets (Pack size	$100.0K	2
Arpimune me 100MG capsules	$60.8K	2
Mofetyl 500 MG tabs (3 x 10's)	$50.0K	1
Vaccine for human medicine - [single	$50.0K	1
Arpimune me 50MG capsules	$50.0K	1
Mofetyl 500MG tabs 3x10's 12337	$50.0K	1
Azathioprine 50MG tablets 10x10's 48335	$50.0K	1
Azathioprine 50MG tablets (10x10's)	$48.9K	1
Azathioprine 50 MG tablets (10 x 10's)	$47.4K	1
Azathioprine 50 MG tablets (10 x 10's) (27550.000 Box)	$42.7K	1
Mofetyl 500MG tabs (3x10's) egypt	$33.7K	1
Arpimune 100 MG capsules (10 x 5's) eg	$31.5K	1
Arpimune 100MG capsules(10x5's	$31.3K	1

International Trading Office imports 52 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Azathioprine	Immunosuppressants	$414.6K	9	1.2%	14
2	Cyclosporine	Immunosuppressants	$111.6K	4	0.9%	12

International Trading Office imports 2 pharmaceutical products across 1 categories into Egypt totaling $526.2K.

International Trading Office — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

International Trading Office (ITO) is a privately-owned healthcare company established in 1992, headquartered in Giza, Egypt. With over 30 years of experience, ITO has emerged as a prominent importer and distributor of vaccines, biological products, immunosuppressants, and critical care pharmaceuticals within Egypt. The company's mission is to unite science, technology, and talent to enhance the quality of life for individuals by providing access to essential healthcare products.

ITO's portfolio includes a wide range of imported products, notably essential vaccines and immunosuppressants sourced from leading global manufacturers. The company has been supplying the Egyptian Ministry of Health with these products for over two decades, underscoring its significant role in the nation's healthcare supply chain.

2Distribution Network

ITO's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across Egypt. While specific warehouse locations are not publicly disclosed, the company emphasizes its capability to provide world-class products to the Egyptian market. This suggests a well-established logistics infrastructure capable of meeting the diverse needs of the healthcare sector.

3Industry Role

In Egypt's pharmaceutical supply chain, ITO functions primarily as an importer and distributor. By sourcing essential vaccines and immunosuppressants from leading global manufacturers, ITO plays a crucial role in ensuring the availability of critical healthcare products within the country. Its longstanding relationship with the Egyptian Ministry of Health highlights its integral position in the national healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — International Trading Office

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

ITO's sourcing strategy exhibits a high degree of concentration, with a total import value of $526,000 USD from India across 13 shipments, focusing on two primary products: Azathioprine and Cyclosporine. This concentrated sourcing approach indicates a strategic choice to maintain strong, stable relationships with key suppliers, ensuring consistent product quality and availability. The substantial import value and the number of shipments suggest a well-established and reliable partnership with these Indian manufacturers.

2Supply Chain Resilience

ITO's supply chain resilience is bolstered by its partnerships with reputable Indian suppliers, RPG Life Sciences Limited and Serum Institute of India Private Limited. The company's focus on finished pharmaceutical formulations, rather than raw APIs or bulk drugs, indicates a preference for ready-to-use products, potentially reducing lead times and simplifying logistics. However, the reliance on a limited number of suppliers for specific products may expose ITO to risks related to supply disruptions or regulatory changes affecting these suppliers.

3Strategic Implications

Importing Pharmaceuticals into Egypt — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Egypt

1Regulatory Authority & Framework

The Egyptian Drug Authority (EDA) is the primary regulatory body overseeing the pharmaceutical sector in Egypt. Key legislation governing pharmaceutical imports includes Ministerial Decree No. 174 of 1999, which stipulates that pharmaceutical products must be registered and approved by the Ministry of Health (MoH) before importation. Additionally, the Pharmacy Law requires that imported pharmaceutical products be registered with the MoH and comply with specific packaging and labeling standards.

2Import Licensing & GMP

Import licensing in Egypt mandates that pharmaceutical companies be registered with the General Organization for Export and Import Control (GOEIC) and the MoH. The importing company must be fully owned and managed by Egyptian nationals. Imported pharmaceutical products must be registered with the MoH and comply with specific packaging and labeling requirements. The MoH also requires that imported products be sourced from manufacturing companies registered with the Ministry of Industry (MoI).

3Quality & Labeling

International Trading Office — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

ITO's focus on importing immunosuppressants, particularly Azathioprine and Cyclosporine, aligns with the growing demand for these critical care pharmaceuticals in Egypt. The company's strategic emphasis on these products indicates a commitment to addressing specific healthcare needs within the country. By sourcing these products from reputable Indian manufacturers, ITO ensures the availability of high-quality medications essential for patient care.

2Sourcing Profile

ITO's sourcing strategy centers on finished pharmaceutical formulations, specifically immunosuppressants, sourced from two primary Indian suppliers: RPG Life Sciences Limited and Serum Institute of India Private Limited. This approach reflects a preference for ready-to-use products, potentially reducing lead times and simplifying logistics. The focus on a limited number of suppliers suggests a strategic choice to maintain strong, stable relationships, ensuring consistent product quality and availability.

3Market Positioning

By importing and distributing essential immunosuppressants, ITO serves a critical segment of the Egyptian healthcare market, particularly in the areas of critical care and specialized treatments. The company's role in supplying these specialized products positions it as a key player in meeting the needs of hospitals, clinics, and healthcare providers requiring high-quality immunosuppressive therapies.

Seller's Guide — How to Become a Supplier to International Trading Office

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with ITO, especially in expanding the range of immunosuppressants and other critical care pharmaceuticals. By offering products that complement ITO's existing portfolio, new suppliers can tap into the growing demand for specialized medications in Egypt. Additionally, exploring alternative formulations or delivery methods could address unmet needs within the Egyptian market.

2Requirements & Qualifications

Indian exporters seeking to supply ITO and the Egyptian market must ensure that their products are registered with the MoH and comply with Egyptian packaging and labeling standards. Additionally, the exporting company must be registered with the GOEIC and the MoH, with ownership and management by Egyptian nationals. Compliance with these regulatory requirements is essential for successful market entry and distribution within Egypt.

3How to Approach

To establish a partnership with ITO, Indian exporters should initiate contact to discuss potential collaboration opportunities. Participating in relevant tenders and aligning with ITO's product portfolio can enhance the likelihood of successful engagement. Understanding and adhering to Egypt's regulatory requirements, including product registration and compliance with local standards, is crucial. A clear timeline for regulatory filing and market entry should be developed to facilitate a smooth partnership.

Frequently Asked Questions — International Trading Office

What products does International Trading Office import from India?

International Trading Office imports 2 pharmaceutical products across 1 categories. Top imports: Azathioprine ($414.6K), Cyclosporine ($111.6K).

Who supplies pharmaceuticals to International Trading Office from India?

International Trading Office sources from 2 verified Indian suppliers. The primary supplier is Rpg Life Sciences Limited (92.9% of imports, $963.7K).

What is International Trading Office's total pharmaceutical import value?

International Trading Office's total pharmaceutical import value from India is $526.2K, based on 13 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does International Trading Office focus on?

International Trading Office imports across 1 categories. The largest: Immunosuppressants (100.0%).

Get Full International Trading Office Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.